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Summary: The 15-kDa selenoprotein (Sepl5) was identified several years 
ago as a protein of unknown function. In recent years, several lines of 
evidence implicated Sepl5 in the effect of dietary selenium in cancer 
prevention. These lines of evidence include: 1) protein expression patterns in 
normal and malignant cells; 2) identification of polymorphic sites that 
regulate Sepl 5 levels and differentially respond to selenium 
supplementation; 3) location of the Sepl5 gene in the human genome; and 4) 
correlation between Sepl5 haplotype and susceptibility to cancer. Functional 
analyses revealed a specific interaction between Sep 15 and a protein folding 
sensor in the endoplasmic reticulum of mammalian cells and identified 
Sep 15 as a novel thioredoxin-like fold redox regulator. Sep 1 5 defines a new 
protein family that occurs in several organisms fiom green algae to mammals 
and also contains selenoprotein M (SelM) and a recently identified fish- 
specific selenoprotein Fep 15. 
Introduction 
Selenium, an important micronutrient, has been implicated in reducing the 
incidence of cancer in different animal models and human clinical trials [I- 
31. As discussed in many chapters in this book, this trace element is 
incorporated into proteins in the form of selenocysteine and is often present 
at the active centers of selenium-containing enzymes. This chapter describes 
one such protein, designated the 1 5 -kDa selenoprotein (Sep 1 5). Sep 1 5 was 
identified in 1998 by purifLing and characterizing a protein fiom human T 
cells [4]. This protein was subsequently implicated in the cancer prevention 
effect of dietary selenium [5], and more recently in regulation of redox 
homeostasis in the endoplasmic reticulum (ER) [6]. This chapter provides up 
to date information on Sepl5 and members of its family. 
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Potential role of SeplS in cancer prevention 
Several selenoproteins have been proposed as candidates that are responsible 
for the cancer prevention potential of selenium. Among these proteins is 
Sepl5 that has been implicated in mediating the chemopreventive effect of 
selenium in certain types of cancers, including liver [5], prostate [7], breast 
181, and lung malignancies [9]. 
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Figure 1. Structural organization of the human SeplS gene. The upper panel shows exon- 
intron organization of the SeplS gene. Closed squares correspond to exons, and horizontal 
lines correspond to introns and flanking regions. The lower panel shows organization of the 
human SeplS cDNA sequence. The relative positions of the ATG initiation and the TGA Sec 
codons, the TAA termination signal and the single nucleotide polymorphisms (8 11C/T and 
1125GJA) are indicated. The long horizontal line corresponds to the Sepl5 cDNA, and short 
vertical lines correspond to exon-exon junctions. Numbers under junction sites correspond to 
last nucleotides in preceding exons. 
The following lines of evidence make an argument for a possible role of 
Sepl5 in cancer etiology. The human gene encoding Sepl5 is located on 
chromosome 1 at position p31, a locus commonly deleted or mutated in 
human cancers and implicated in tumor suppression [ 10,111. Sep 15 
expression was found to be significantly decreased in more than half of the 
tested cancer samples and tumor cell lines as compared to corresponding 
controls [5,9]. Genetic analysis of the human Sepl5 gene revealed the 
presence of two polymorphisms that show strong allelic association [5]. 
These two single nucleotide polymorphisms (SNPs) are located at positions 
8 1 1 (C/T) and 1 125 (GIA) in the Sep 15 mRNA (see Figure 1). The latter 
polymorphism is, in fact, part of the SECIS element, an RNA structure in the 
3'-untranslated region required for recognition of in-frame UGA codons as 
selenocysteine. This SNP appears to influence expression of Sepl5 in a 
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selenium-dependent manner. The A1125 variant resulted in a higher 
expression of the selenoprotein, but it could not efficiently respond to the 
addition of selenium in the cell culture medium [5,7,12]. Thus, this SNP 
directly influenced the expression levels of Sepl5, and the outcome was 
dependent on the selenium status. These data suggested that individuals 
differing in these alleles may not only differ in Sepl5 levels but also in the 
response to selenium dietary supplements. The polymorphisms have further 
relevance to cancer. The A1 125 form is prevalent in African Americans who 
are known to have a higher incidence of prostate cancer [7]. It also should be 
noted that the highest expression of Sepl5 is observed in the prostate [5]. It 
is conceivable that African Americans require higher levels of selenium to 
achieve the protective levels of Sepl5 expression. In addition, it was found 
that African Americans showed differences in allelic frequency in head, 
neck, and breast cancers and examples of the loss of heterozygosity at the 
Sep 15 locus also were observed [7]. 
Recent studies from other groups provide further evidence in support of 
these observations. For example, the A1 125 form was found to be less 
responsive than the G1125 form to the selenium that showed growth 
inhibitory and apoptotic effects [9]. 
Interaction of Sepl5 with UDP-glucose:glycoprotein glucosyltransferase 
During initial purification from a human T-cell line, Sepl5 was isolated in 
the denatured state [4]; however, native Sepl5 isolated from rat prostate and 
mouse liver co-purified with a protein of -160-240 kDa. The binding partner 
of Sepl5 was identified as UDP-glucose:glycoprotein glucosyltransferase 
(UGT), an ER chaperone and essential regulator of the calnexin cycle [6]. 
The calnexin cycle is a quality control pathway localized to the ER that 
specifically assists in the folding of N-linked glycoproteins [13]. In this 
quality control pathway, UGT functions as the folding sensor that recognizes 
unfolded or improperly folded glycoproteins (Figure 2). UGT catalyzes the 
transfer of a glucose moiety from UDP-glucose to the glycan core [14] that 
creates a retention signal and initiates binding of membrane-bound calnexin 
and its lumenal homologue calreticulin to the glycan [15-181. This triggers 
the binding of ERp57 (a lurnenal protein disulfide isomerase) to calnexin and 
calreticulin, and accelerates folding by catalyzing disulfide bond exchange 
[19-231. The tight association of Sepl5 and UGT in 1 : 1 ratio (with apparent 
Kd of 20 nM) suggests that this selenoprotein may modulate the enzymatic 
activity of UGT and/or be involved in assessing structural fidelity [24]. This 
role is also supported by the observation that expression of Sepl5 is 
activated by the unfolded protein response (UPR), a signaling pathway 
activated in response to accumulation of unfolded proteins in the ER [25]. 
The W R  pathway results in enhanced expression of genes encoding proteins 
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that facilitate protein folding and help cells remove incorrectly folded and/or 
excess proteins in the ER. 
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Figure 2. Sepl5 and the quality control pathway. UGT recognizes unfolded or improperly 
folded glycoproteins and catalyzes the transfer of a glucose residue to the glycan. This creates 
a retention signal and initiates the calnexin/calreticulin cycle. A protein disulfide isomerase 
binds to calnexin and calreticulin and isomerizes incorrectly formed disulfide bonds. Finally, 
glucose residue is cleaved by glucosidase, and properly folded glycoproteins are exported 
form the ER. If not, they are recognized by UGT and the calnexidcalreticulin cycle repeats. 
The possible functions of Sepl5 in this pathway are shown by open arrows and question 
marks. 
Sequence analysis of the Sepl5 family members identified two distinct 
domains within this selenoprotein: a C-terminal thioredoxin-like domain that 
contains the redox active CxU motif and a novel cysteine-rich domain 
located in the N-terminal part of the protein (Figure 3). The latter domain 
exclusively mediates the interaction with UGT and contains six cysteine 
residues, which are highly conserved among Sepl5 proteins. In contrast to 
Sepl 5 ,  this domain is absent in its homologue selenoprotein M (SelM), and 
SelM does not interact with UGT. Mutational studies have shown that 
substitution of any of the six conserved cysteine residues with serines 
disrupts the interaction between Sepl5 and UGT. As four of these six 
cysteines form a pair of CwrC motifs, there was a possibility that these motifs 
were involved in coordination of metal ions. However, neither cysteine-rich 
domain itself coordinated metal ions, nor was the formation of Sepl 5-UGT 
complex mediated by metals [24] suggesting that these conserved cysteine 
residues likely form intramolecular disulfide bonds. Site-directed 
mutagenesis of cysteine residues may disrupt proper arrangement of the 
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disulfide bonds and inhibit protein-protein interaction between Sepl5 and 
UGT. 
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Figure 3. Schematic illustration of the domain arrangement of SeplS and SelM. Both 
selenoproteins encode an N-terminal signal peptide (colored black); one selenocysteine (U) 
residue; and a thioredoxin-like domain (colored gray). The N-terminal extension of Sep 15 
containing six highly conserved cysteine residues has been labeled as the UGT-binding 
domain. 
Consistent with the ER localization of UGT, SeplS was also localized to 
the ER, and its N-terminal signal peptide, which was cleaved in the mature 
protein, was necessary for the ER translocation [6]. In contrast, the C- 
terminus of SeplS lacked a typical ER retention signal suggesting that 
location of Sepl5 in this cellular compartment is the result of the interaction 
with UGT via the N-terminal cysteine-rich domain. 
Thiol-disulfide oxidoreductase function 
The solution NMR structures of the thioredoxin-like domain of SeplS fiom 
Drosophila melanogaster and SelM fiom Mus musculus have been identified 
[26]. The structural studies revealed that both Sepl5 and SelM have a 
thioredoxin-like fold and suggested a thiol-disulfide oxidoreductase function 
for these selenoproteins. Although the precise biological function of Sepl5 
remains unknown, its surface-accessible CxU motif, located in the C- 
terminal redox domain, may participate in the reduction, isomerization or 
oxidation of disulfide bonds and facilitate protein folding (Figure 2). The 
redox potential of Drosophila Sepl5, which naturally encodes a cysteine 
residue in place of the selenocysteine in the redoxactive CxU motif, was 
measured to be -225 mV. This redox potential is higher than that of the 
strong disulfide reductant thioredoxin (-270 mV [27,28]), but is lower than 
that of the dithiol oxidase DsbA (-122 rnV [29,30]). However, the redox 
potential of SeplS is within the range of the redox potentials of disulfide 
reshuffling enzymes, such as PDI (-1 75 mV [27]), indicating that Sepl 5 may 
fbnction as a disulfide isomerase. Although the measured redox potential is 
close to that of the protein disulfide isomerase, the possibility cannot be 
excluded that biological activity of Sepl5 in vivo may be affected by protein- 
protein interactions with other ER resident proteins and available 
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donors/acceptors of electrons. Furthermore, in contrast to protein disulfide 
isomerase and its broad substrate specificity, Sepl5 may service a restricted 
group of protein substrates as demonstrated for protein disulfide isomerase 
ERp57, which functions exclusively as an isomerase for partially folded 
glycoproteins that are bound to the chaperones calnexin and calreticulin 
[19,22,3 11. In this case, UGT, which recognizes improperly folded 
glycoproteins, may serve as a primary binding site for Sepl5 protein 
substrates (analogous to the role of non-catalytic bt-domain of human protein 
disul fide isomerase). 
Expression pattern and regulation of Sepl5 expression by dietary 
selenium 
Expression of the Sepl5 gene was examined in several mouse and human 
tissues by northern blot and immunoblot analyses [5]. The highest levels of 
gene expression were observed in prostate, liver, kidney, testes and brain, 
while lower levels were found in lung, spleen and skeletal muscle. 
Dietary selenium has been shown to regulate the expression of 
selenoproteins and the abundance of corresponding mRNAs by acting at both 
transcriptional and translational levels. For example, selenium deficiency is 
known to result in up to a 99% decrease in the activity of glutathione 
peroxidase 1 (GPxl) and in up to a 90% decrease in the abundance of GPxl 
mRNA in livers of rats and mice. Similar to GPxl, Sepl5 expression was 
also regulated by selenium availability in liver and kidney, although the 
changes in expression were less pronounced [26,32]. In contrast, Sepl5 
expression in testes remained almost constant regardless of the selenium 
availability, consistent with previous observations that the expression 
patterns of selenoproteins localized to the liver and kidney are highly 
responsive to the availability of selenium, while the testes efficiently retain 
this element under selenium-deficient conditions [33,34]. 
Sepl5 selenoprotein family members 
Sepl5 is highly conserved from plants to humans [4] suggesting an 
evolutionary conserved physiological function among Sep 1 5 proteins. 
Another ER resident eukaryotic selenoprotein, SelM, a distant homolog of 
Sepl 5, has recently been identified and characterized [35]. SelM and Sepl5 
share 31% sequence identity in their proposed redox-active domains and 
encode an N-terminal signal peptide (see Figure 3), which is cleaved in the 
mature protein after translocation into the ER. In contrast to Sepl5, the 
cysteine-rich UGT-binding domain is absent in SelM, and SelM is likely 
retained in the ER by a C-terminal retention signal (H/R/K-X-DL). This 
selenoprotein shows a different expression pattern than Sep 15, with the 
highest expression in the brain. Although the function of SelM has not been 
firmly established, recent studies provide evidence that decreased expression 
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of this protein is associated with Alzheimer's disease and SelM may be 
involved in protection of neurons from oxidative damage [36]. 
Recently, a new selenoprotein distantly homologous to Sepl5 family 
members has been identified [37]. This selenoprotein was found only in fish 
and was designated Fepl5 (for fish SeplS-like protein). As observed with 
SelM, Fepl5 contains a known ER retention signal (RDEL) at its C-terminus 
and was also localized to the ER. Fepl5 encodes a single selenocysteine 
residue. In contrast to Sepl5, in which Sec is organized into highly 
conserved CxU motif, and SelM, in which Sec is present within CsucU motif, 
FeplS has valine in place of the conserved cysteine. Moreover, Fepl5 does 
not have any conserved cysteine residues, and in some of the FeplS 
sequences cysteines are not present at all. Thus, this selenoprotein has a 
distinct catalytic mechanism that may involve formation of selenenic acid or 
selenenylsulfide bond with a cysteine residue in another protein or low 
molecular weight thiol, such as glutathione 1381. Another unique feature of 
this novel selenoprotein is that it is present exclusively in selenocysteine- 
containing form, while other members of the SeplS protein family exist in 
the form of both selenocysteine- and cysteine-containing proteins. 
Furthermore, the very narrow distribution of Fepl5 among fishes suggests 
that this protein may have a highly specialized function. 
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